Meningococcal Vaccines Market Size, Share, Trends, Growth Outlook

Meningococcal Vaccines Market is estimated to increase at a growth rate of 7.9% CAGR over the forecast period from 2024 to 2030.

The global Meningococcal Vaccines Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Bivalent, Quadrivalent, Others), By Brand (Menactra, Menveo, Nimenrix, Trumenba, Bexsero, Others), By Age group (Infants, Children, Adults), By Serotype (Serotype A, Serotype B, Serotype C, Serotype W-135, Serotype Y), By Sales Channel (Private, Public).

An introduction to Meningococcal Vaccines Market in 2024

Vital in preventing meningococcal disease caused by Neisseria meningitidis bacteria, the Meningococcal Vaccines market addresses public health concerns by offering immunization solutions against various serogroups of the meningococcus bacterium. These vaccines, available in conjugate, polysaccharide, and combination formulations, provide protection against meningitis and septicemia, particularly in high-risk populations such as infants, adolescents, and travellers to endemic regions. The market's growth is driven by vaccination campaigns, expanding awareness of the meningococcal disease, and advancements in vaccine technologies enhancing immunogenicity and coverage against multiple serogroups.

Meningococcal Vaccines Market Trend: Increasing Focus on Vaccination Programs and Disease Prevention

A significant trend in the Meningococcal Vaccines market is the increasing focus on vaccination programs and disease prevention initiatives aimed at reducing the global burden of meningococcal disease. Governments, healthcare organizations, and public health agencies are prioritizing immunization efforts to control meningococcal outbreaks and protect populations at risk. Meningococcal vaccines are becoming an essential component of routine vaccination schedules, with expanded recommendations for immunization in high-risk groups such as infants, adolescents, college students, and travelers to meningitis-endemic regions. The trend towards proactive disease prevention strategies and the adoption of meningococcal vaccination programs reflects the growing recognition of the importance of vaccination in reducing morbidity, mortality, and healthcare costs associated with meningococcal infections.

Meningococcal Vaccines Market Driver: Increasing Incidence of Meningococcal Disease and Outbreaks

A key driver for the Meningococcal Vaccines market is the increasing incidence of meningococcal disease worldwide and the occurrence of outbreaks in various regions. Meningococcal disease is a severe and potentially life-threatening bacterial infection caused by Neisseria meningitidis, with manifestations ranging from meningitis to septicemia. The disease can result in serious complications, including neurological impairment, limb amputation, and death, particularly in unvaccinated individuals and populations with low vaccine coverage. The rising incidence of meningococcal disease, coupled with the emergence of new serogroups and strains, underscores the urgent need for effective vaccination strategies to control outbreaks, protect vulnerable populations, and prevent the spread of infection. The need for comprehensive immunization programs and enhanced vaccine coverage drives market demand for meningococcal vaccines, supporting research, development, and deployment efforts to address the global burden of meningococcal disease.

Meningococcal Vaccines Market Opportunity: Expansion into New Vaccine Formulations and Serogroup Coverage

An opportunity within the Meningococcal Vaccines market lies in the expansion into new vaccine formulations and broader serogroup coverage, offering enhanced protection against meningococcal infections and addressing evolving disease epidemiology. Manufacturers can explore opportunities to develop multivalent vaccines that provide immunity against multiple meningococcal serogroups, including serogroups A, B, C, W, and Y, to offer comprehensive protection against diverse strains and serotypes. Additionally, there is potential to innovate vaccine technologies such as recombinant protein-based vaccines, conjugate vaccines, and novel adjuvant formulations to improve vaccine efficacy, safety, and immunogenicity. By expanding into new vaccine formulations and broader serogroup coverage, manufacturers can address unmet medical needs, improve vaccine accessibility, and contribute to global efforts to eliminate meningococcal disease, thus driving growth and innovation in the Meningococcal Vaccines market.

Meningococcal Vaccines Market Market Segmentation

By Type
Bivalent
Quadrivalent
Others
By Brand
Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others
By Age Group
Infants
Children
Adults
By Serotype
Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y
By Sales Channel
Private
Public

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Meningococcal Vaccines Market Companies

Bio-Manguinhos
Biomed Pvt. Ltd
GlaxoSmithKline plc
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi Pasteur Inc
Serum Institute of India Ltd

Reasons to Buy the Meningococcal Vaccines Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Meningococcal Vaccines Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Meningococcal Vaccines Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Meningococcal Vaccines Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Meningococcal Vaccines Market Size Outlook, $ Million, 2021 to 2030
3.2 Meningococcal Vaccines Market Outlook by Type, $ Million, 2021 to 2030
3.3 Meningococcal Vaccines Market Outlook by Product, $ Million, 2021 to 2030
3.4 Meningococcal Vaccines Market Outlook by Application, $ Million, 2021 to 2030
3.5 Meningococcal Vaccines Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Meningococcal Vaccines Industry
4.2 Key Market Trends in Meningococcal Vaccines Industry
4.3 Potential Opportunities in Meningococcal Vaccines Industry
4.4 Key Challenges in Meningococcal Vaccines Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Meningococcal Vaccines Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Meningococcal Vaccines Market Outlook by Segments
7.1 Meningococcal Vaccines Market Outlook by Segments, $ Million, 2021- 2030
By Type
Bivalent
Quadrivalent
Others
By Brand
Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others
By Age Group
Infants
Children
Adults
By Serotype
Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y
By Sales Channel
Private
Public

8 North America Meningococcal Vaccines Market Analysis and Outlook To 2030
8.1 Introduction to North America Meningococcal Vaccines Markets in 2024
8.2 North America Meningococcal Vaccines Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Meningococcal Vaccines Market size Outlook by Segments, 2021-2030
By Type
Bivalent
Quadrivalent
Others
By Brand
Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others
By Age Group
Infants
Children
Adults
By Serotype
Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y
By Sales Channel
Private
Public

9 Europe Meningococcal Vaccines Market Analysis and Outlook To 2030
9.1 Introduction to Europe Meningococcal Vaccines Markets in 2024
9.2 Europe Meningococcal Vaccines Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Meningococcal Vaccines Market Size Outlook by Segments, 2021-2030
By Type
Bivalent
Quadrivalent
Others
By Brand
Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others
By Age Group
Infants
Children
Adults
By Serotype
Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y
By Sales Channel
Private
Public

10 Asia Pacific Meningococcal Vaccines Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Meningococcal Vaccines Markets in 2024
10.2 Asia Pacific Meningococcal Vaccines Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Meningococcal Vaccines Market size Outlook by Segments, 2021-2030
By Type
Bivalent
Quadrivalent
Others
By Brand
Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others
By Age Group
Infants
Children
Adults
By Serotype
Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y
By Sales Channel
Private
Public

11 South America Meningococcal Vaccines Market Analysis and Outlook To 2030
11.1 Introduction to South America Meningococcal Vaccines Markets in 2024
11.2 South America Meningococcal Vaccines Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Meningococcal Vaccines Market size Outlook by Segments, 2021-2030
By Type
Bivalent
Quadrivalent
Others
By Brand
Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others
By Age Group
Infants
Children
Adults
By Serotype
Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y
By Sales Channel
Private
Public

12 Middle East and Africa Meningococcal Vaccines Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Meningococcal Vaccines Markets in 2024
12.2 Middle East and Africa Meningococcal Vaccines Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Meningococcal Vaccines Market size Outlook by Segments, 2021-2030
By Type
Bivalent
Quadrivalent
Others
By Brand
Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others
By Age Group
Infants
Children
Adults
By Serotype
Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y
By Sales Channel
Private
Public

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Bio-Manguinhos
Biomed Pvt. Ltd
GlaxoSmithKline plc
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi Pasteur Inc
Serum Institute of India Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Bivalent
Quadrivalent
Others
By Brand
Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others
By Age Group
Infants
Children
Adults
By Serotype
Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y
By Sales Channel
Private
Public